By SaiyanMed Research Team · Updated 5 November 2026 · For in-vitro research use only · Not sold by SaiyanMed
EXPLICIT NO-SKU / NO-STOCK BANNER — READ FIRST. Orforglipron (Foundayo™) is an FDA-approved prescription medicine (oral small-molecule GLP-1 receptor agonist) sponsored by Eli Lilly. SaiyanMed does NOT sell Foundayo, orforglipron tablets, orforglipron “research powder,” “oral GLP-1 raw,” or any substitute SKU. This hub is educational literacy only — chemistry and trial-program context for researchers comparing non-peptide oral GLP-1 agonists vs peptide incretins (semaglutide, tirzepatide, retatrutide, and related RUO peptides). Never treat this page as a stocking brief, wholesale sourcing note, compounding recipe, buy path, or personal-use guide. No Add to Cart. No product link. No “coming soon” inventory tease.
RESEARCH-LITERACY DISCLAIMER (NOT A USE GUIDE). Content summarizes public FDA / Lilly IR / ClinicalTrials.gov / peer-reviewed information for laboratory and scientific literacy. It is not medical advice, veterinary advice, prescribing information, a Medication Guide substitute, reconstitution guidance, titration advice, or authorization for human or animal self-administration. Approved-label dosing belongs only on the official Prescribing Information — this article does not provide a dosing schedule. Trial milligram labels (capsule vs tablet equivalents) are study identifiers, not laboratory recipes.
Quick answer
Orforglipron (development code LY3502970; U.S. brand Foundayo™) is Eli Lilly’s once-daily oral small-molecule (non-peptide) glucagon-like peptide-1 (GLP-1) receptor agonist. It was discovered at Chugai Pharmaceutical and licensed by Lilly in 2018 [Lilly ATTAIN-1 IR 2025-08-07; PNAS DOI 10.1073/pnas.2014879117].
On 1 April 2026, the U.S. FDA approved Foundayo (orforglipron) tablets, with diet and increased physical activity, to reduce excess body weight and maintain weight reduction long term in adults with obesity, or adults with overweight plus at least one weight-related comorbid condition. FDA described it as a GLP-1 receptor agonist in tablet form taken orally once daily, and as the first new molecular entity (NME) approved under the Commissioner’s National Priority Voucher (CNPV) pilot [FDA press 2026-04-01; Lilly Foundayo approval IR 2026-04-01; NDA 220934 approval package].
Why this hub exists on SaiyanMed: researchers comparing incretin modalities constantly ask how an oral non-peptide GLP-1 agonist differs from injectable peptide incretins (and from peptide RUO powders). This page answers that chemistry / modality question. It does not create a catalog SKU.
Orforglipron is not the same molecule as:
| Peer (research context) | Public MoA / modality headline | Why it is different |
|---|---|---|
| Semaglutide | Mono GLP-1 peptide (injectable and separate oral peptide products exist as approved medicines) | Peptide backbone vs non-peptide small molecule; different absorption / formulation problems |
| Tirzepatide | Dual GIP / GLP-1 peptide | Dual agonist peptide — not a mono small-mol GLP-1 tablet API |
| Retatrutide | Unimolecular GIP / GLP-1 / glucagon peptide triple | Triple peptide agonist; injectable research theme |
| VK2735 | Dual GIP / GLP-1 peptide (SC + oral peptide tablet programs) | Still a peptide dual agonist — oral program ≠ same chemistry as orforglipron |
| Zenagamtide | Unimolecular GLP-1 + amylin peptide | Amylin pathway; peptide |
| Survodutide | Dual glucagon / GLP-1 peptide | GCGR dual; peptide |
| MariTide | Ab–peptide conjugate (GLP-1 agonism + GIPR antagonism) | Biologic conjugate, not a small-molecule tablet |
Small molecule vs peptide incretins (why the chemistry differs)
What “non-peptide oral GLP-1 RA” means
Sponsor and structural literature describe orforglipron / LY3502970 as an orally active nonpeptide GLP-1 receptor agonist — a small molecule, not a chain of amino acids [PNAS DOI 10.1073/pnas.2014879117; Lilly ATTAIN-1 IR 2025-08-07]. FDA’s approval announcement likewise frames Foundayo as a GLP-1 receptor agonist in tablet form for once-daily oral use [FDA press 2026-04-01].
Lilly’s public “About” language emphasizes a once-daily small molecule (non-peptide) oral GLP-1 receptor agonist that can be taken any time of day without food and water restrictions (citing food-effect PK work) [Lilly ACHIEVE-4 IR 2026-04-16; Lilly ATTAIN-1 IR 2025-08-07].
Peptide incretins live in a different chemical / analytical world
Typical SaiyanMed catalog peers (semaglutide-, tirzepatide-, retatrutide-class peptides) are synthetic polypeptides. Their RUO identity problems are peptide problems: sequence/length, lipidation or other modifications, isomer content, aggregation, residual TFA/solvents, peptide content vs salt, and intact-mass confirmation.
Orforglipron’s public identity is a small-molecule drug substance / drug product:
| Dimension | Peptide incretin (e.g. retatrutide / tirzepatide / semaglutide class) | Orforglipron (Foundayo) |
|---|---|---|
| Chemical class | Amino-acid polymer (peptide / modified peptide) | Non-peptide small molecule |
| Typical clinical presentation (sponsor) | Often subcutaneous injection (some oral peptide products use special absorption strategies) | Oral tablet once daily [FDA] |
| Receptor headline | Mono / dual / triple peptide agonists (program-dependent) | Mono GLP-1R small-mol agonist |
| RUO COA mindset | RP-HPLC + intact-mass LC-MS + peptide content | Would need small-molecule identity/assay/impurity methods — not a peptide purity chromatogram alone |
| SaiyanMed catalog fit | Possible peptide SKUs with COA (product-dependent) | Never — approved small-molecule medicine; educational hub only |
Structural literacy
Kawai et al. (PNAS 2020) report the structural basis for GLP-1 receptor activation by LY3502970, an orally active nonpeptide agonist — the primary chemistry citation Lilly itself footnotes in ATTAIN IR [DOI 10.1073/pnas.2014879117; Lilly ATTAIN-1 IR]. Treat that paper as mechanistic / structural context, not as a synthesis route, impurity method, or compounding instructions.
- Sharing a GLP-1R agonist headline with semaglutide does not make orforglipron a “semaglutide pill” or a peptide vial equivalent.
- Oral peptide programs (e.g. oral semaglutide medicines; oral VK2735 peptide tablets in Viking’s pipeline) solve a different formulation problem than a non-peptide small molecule.
- Cross-trial % weight loss is not a clinical ranking of “which molecule is better for patients.”
ATTAIN program (obesity / overweight)
Figures below are trial-reported outcomes from Lilly IR, Lilly Medical, ClinicalTrials.gov results postings, and the NEJM ATTAIN-1 citation. They are not dosing instructions, eligibility advice, or product claims for research materials.
Program snapshot
| Trial | NCT | Population (high-level) | Status (CT.gov fetch 2026-11-05) | Size |
|---|---|---|---|---|
| ATTAIN-1 | NCT05869903 | Obesity / overweight + comorbidity; without T2D; 72-week primary weight endpoint | Results posted; overall status ACTIVE_NOT_RECRUITING (primary completion 2025-07-25 actual; study completion est. 2027-10) | n=3127 actual |
| ATTAIN-2 | NCT05872620 | Obesity / overweight with T2D | COMPLETED (primary completion 2025-08-08 actual); results posted | n=1613 actual |
Lilly states the ATTAIN Phase 3 program enrolled more than 4,500 people with obesity or overweight across the two global registration trials [Lilly Foundayo approval IR 2026-04-01; Lilly ATTAIN-1 IR 2025-08-07].
Capsule vs tablet milligram labels (literacy only — not a conversion recipe)
ATTAIN registries and the August 2025 Lilly topline use capsule maintenance labels 6 / 12 / 36 mg. Lilly Medical’s post-approval ATTAIN-1 summary restates the same arms as tablet-equivalent maintenance labels 5.5 / 9 / 17.2 mg, noting the study used an investigational capsule formulation and presenting tablet-equivalent doses aligned to the U.S. approved tablet strengths [Lilly Medical ATTAIN-1; Lilly ATTAIN-1 IR]. ACHIEVE-4 similarly notes capsule↔tablet correspondence language in escalation framing [Lilly ACHIEVE-4 IR 2026-04-16].
Compliance: Do not invent a DIY “capsule-to-powder” or “tablet crush” protocol from these equivalences.
ATTAIN-1 weight outcomes
Peer-reviewed pointer: Wharton S, et al. N Engl J Med. 2025;393(18):1796–1806. DOI 10.1056/NEJMoa2511774 [DOI; Lilly Medical refs].
Efficacy estimand (Lilly IR primary topline table) @ 72 weeks [Lilly ATTAIN-1 IR 2025-08-07]:
| Arm (capsule label / tablet-equivalent) | Mean % weight change | Notes |
|---|---|---|
| 6 mg ≈ 5.5 mg | −7.8% (−8.0 kg / −17.6 lbs) | Baseline mean weight 103.2 kg, BMI 37.0 |
| 12 mg ≈ 9 mg | −9.3% (−9.4 kg / −20.7 lbs) | |
| 36 mg ≈ 17.2 mg | −12.4% (−12.4 kg / −27.3 lbs) | Headline “up to 27.3 lbs” |
| Placebo | −0.9% (−1.0 kg / −2.2 lbs) |
Key secondary (≥10% / ≥15% responders, efficacy estimand, high dose): 59.6% / 39.6% vs placebo 8.6% / 3.6% [Lilly ATTAIN-1 IR].
Treatment-regimen estimand (Lilly Medical: primary estimand) @ 72 weeks [Lilly Medical ATTAIN-1; Lilly ATTAIN-1 IR]:
| Arm (tablet-equivalent) | Mean % weight change |
|---|---|
| 5.5 mg | −7.5% |
| 9 mg | −8.4% |
| 17.2 mg | −11.2% |
| Placebo | −2.1% |
Gap flag: Always label which estimand you cite. Do not mix −12.4% (efficacy / high dose) with −11.2% (treatment-regimen / high dose) as if identical.
ATTAIN-1 tolerability (as reported — not advice)
Lilly reports GI events as the most common AEs, generally mild-to-moderate; discontinuation due to AEs 5.1% / 7.7% / 10.3% (6 / 12 / 36 mg) vs 2.6% placebo; no hepatic safety signal observed in the IR narrative [Lilly ATTAIN-1 IR 2025-08-07].
ATTAIN-2 (obesity + T2D) — CT.gov results snapshot
From ClinicalTrials.gov results posting for NCT05872620 (fetch 2026-11-05), least-squares mean % body-weight change (posted primary measure): placebo −2.21; 6 / 12 / 36 mg QD −5.50 / −7.78 / −10.54. Posted HbA1c change (secondary): placebo −0.14; 6 / 12 / 36 mg −1.29 / −1.60 / −1.79 percentage points. Prefer Lilly IR / peer-reviewed ATTAIN-2 publication when expanding narrative beyond this registry snapshot.
ACHIEVE-4 cardiovascular / T2D safety context
ACHIEVE-4 figures are trial-reported cardiovascular and metabolic outcomes vs insulin glargine. This section is not a treatment-choice guide.
On 16 April 2026, Lilly announced topline results from ACHIEVE-4 (NCT05803421) — described as the largest and longest Phase 3 study of Foundayo in type 2 diabetes to date (>2,700 participants; 2,749 randomized per IR) comparing orforglipron with insulin glargine in adults with T2D and obesity/overweight at increased CV risk [Lilly ACHIEVE-4 IR 2026-04-16].
| Endpoint (as stated) | Foundayo vs insulin glargine |
|---|---|
| Primary: time to first MACE-4 | HR 0.84 (95% CI 0.59–1.20); met non-inferiority (upper CI < 1.8) |
| MACE-3 | HR 0.77 (95% CI 0.52–1.13) |
| A1C change @ 52 wk (efficacy estimand; baseline mean 8.22%) | −1.6% vs −1.0% (ETD −0.66) |
| Body weight @ 52 wk (efficacy estimand; baseline mean 90.9 kg) | −8.8% vs +1.7% (ETD −10.42%) |
| All-cause death (pre-planned; not multiplicity-controlled) | HR 0.43 (95% CI 0.25–0.75; nominal p=0.002) |
Lilly states overall safety/tolerability was generally consistent with prior trials and the GLP-1 class; 10.6% discontinued for AEs during the 52-week minimum treatment period; thorough DILI analyses “confirmed there was no hepatic safety signal,” consistent with ACHIEVE and ATTAIN programs [Lilly ACHIEVE-4 IR].
Lilly also stated intent to submit Foundayo for type 2 diabetes to FDA by end of Q2 (under CNPV language in that IR) — treat as sponsor regulatory plan, not as a second approved indication on this hub unless/until an approval press is cited [Lilly ACHIEVE-4 IR].
ACHIEVE program size note: Lilly says ACHIEVE Phase 3 enrolled more than 6,000 people with T2D across five global registrational trials [Lilly ACHIEVE-4 IR].
Why SaiyanMed covers orforglipron (educational compare only)
- Search demand is huge for “what is orforglipron / Foundayo,” but most SERP results are consumer/medical explainers — weak on peptide vs small-molecule literacy that RUO buyers actually confuse.
- SaiyanMed’s catalog and hubs center on research peptides (retatrutide, tirzepatide, semaglutide clusters, zenagamtide, VK2735, etc.). Without an explicit “this is not a peptide vial” page, readers mis-map Foundayo onto grey-market powders.
- Week-focus Top-8 marks orforglipron P2 educational-only with product page policy Never (approved small-molecule drug).
This hub’s job: modality contrast + cited program map.
This hub’s non-jobs: sell, source, compound, titrate, or “stock when API is cheap.”
Contrast with SaiyanMed’s peptide RUO catalog
| Question researchers ask | Evidence-based answer on this hub |
|---|---|
| “Can SaiyanMed stock orforglipron like retatrutide?” | No. Approved small-molecule medicine; no SKU; educational indefinitely. |
| “Is Foundayo just oral semaglutide?” | No. Different API; orforglipron is a non-peptide small molecule [FDA; PNAS]. |
| “Same as oral VK2735?” | No. VK2735 remains a dual GIP/GLP-1 peptide with an oral tablet program [VK2735 hub]. |
| “Same as retatrutide / tirzepatide?” | Different modality and (for reta/TZP) multi-agonist peptide designs [retatrutide hub]. |
| “Grey-market ‘orforglipron powder’ = Foundayo?” | No identity claim. Tablet drug product ≠ unlabeled research chemical. This site does not sell either. |
Related peptide literacy (soft links only — not substitutes): What Is Retatrutide? · What Is VK2735? · What Is Zenagamtide (Amycretin)? · What Is Survodutide? · What Is MariTide? · Tirzepatide vs semaglutide · Tirzepatide mechanism.
Myth vs evidence
| Myth | Evidence-based correction |
|---|---|
| “Orforglipron is a research peptide SaiyanMed can vial.” | It is a non-peptide small molecule; Foundayo is an approved tablet medicine. No SaiyanMed SKU. |
| “Foundayo = oral semaglutide under another name.” | Different API and chemistry class (non-peptide small mol vs peptide) [FDA; PNAS]. |
| “Same as retatrutide because both are ‘next-gen GLP-1’.” | Retatrutide is a triple agonist peptide; orforglipron is mono GLP-1 small molecule [retatrutide hub]. |
| “Same as oral VK2735.” | VK2735 oral program is still a dual GIP/GLP-1 peptide [VK2735 hub]. |
| “−12.4% and −11.2% are the same ATTAIN-1 number.” | Different estimands (efficacy vs treatment-regimen) [Lilly ATTAIN-1 IR]. |
| “ACHIEVE-4 proves T2D is already an approved Foundayo indication.” | ACHIEVE-4 supports a planned FDA submission for T2D per Lilly IR; chronic weight-management approval is what FDA announced 2026-04-01 [ACHIEVE-4 IR; FDA]. |
| “This article’s milligrams are a personal titration plan.” | Explicitly out of scope — use official Prescribing Information only if prescribed; this page provides none. |
Glossary
- Orforglipron / LY3502970 / Foundayo™: Lilly oral non-peptide GLP-1 receptor agonist small molecule; U.S. brand Foundayo.
- Non-peptide / small-molecule GLP-1 RA: GLP-1R agonist that is not an amino-acid peptide chain.
- ATTAIN: Phase 3 obesity/overweight registration program (ATTAIN-1 without T2D; ATTAIN-2 with T2D).
- ACHIEVE: Phase 3 T2D program family; ACHIEVE-4 = CV-risk T2D study vs insulin glargine.
- Efficacy estimand / treatment-regimen estimand: Two ATTAIN analysis frameworks — label which you cite.
- CNPV: FDA Commissioner’s National Priority Voucher pilot (context for Foundayo review timing per FDA).
- RUO: Research Use Only framing for SaiyanMed educational content — not a license to use research chemicals in humans.
- SKU: Stock-keeping unit / product listing — none for orforglipron on SaiyanMed.
FAQ
What is orforglipron?
Orforglipron (LY3502970; Foundayo) is Lilly’s once-daily oral small-molecule non-peptide GLP-1 receptor agonist, discovered at Chugai and licensed by Lilly, FDA-approved 1 April 2026 for chronic weight management in indicated adults with diet and activity [FDA; Lilly approval IR; PNAS].
Does SaiyanMed sell orforglipron / Foundayo?
No. Educational hub only. No product SKU, no buy path, no stocking plan on this page (post/product sitemap check 2026-11-05: no orforglipron/Foundayo URLs).
How is it different from peptide incretins like retatrutide or tirzepatide?
Different chemical class (small molecule vs peptide) and usually different polypharmacology (orforglipron: mono GLP-1R; retatrutide: triple; tirzepatide: dual GIP/GLP-1).
What did ATTAIN-1 show?
At 72 weeks, efficacy-estimand high-dose mean weight change −12.4% vs −0.9% placebo; treatment-regimen high-dose −11.2% vs −2.1% [Lilly ATTAIN-1 IR; Lilly Medical].
What is ACHIEVE-4?
Phase 3 T2D + obesity/overweight CV-risk trial vs insulin glargine showing MACE-4 non-inferiority (HR 0.84, CI upper 1.20 < 1.8 criterion) plus A1C/weight differences as reported [Lilly ACHIEVE-4 IR].
Can I use trial or label milligrams as a protocol?
No. This page provides no dosing, titration, crushing, compounding, or administration guidance.
Key takeaways
- Orforglipron = Foundayo = LY3502970 — Lilly oral non-peptide GLP-1 RA small molecule (Chugai-discovered).
- FDA-approved 2026-04-01 for chronic weight management in indicated adults (with diet/activity) [FDA].
- Not a peptide; not a SaiyanMed RUO vial candidate; no SKU / never stock under this hub’s policy.
- ATTAIN-1: label estimands carefully (−12.4% efficacy vs −11.2% treatment-regimen at high dose, 72 wk).
- ACHIEVE-4: CV non-inferiority vs insulin glargine in high-risk T2D (sponsor IR).
- Use this page to explain chemistry modality; send peptide questions to peptide hubs — not to a fake Foundayo product page.
Related reading & research inquiry
- What Is Retatrutide?
- What Is VK2735?
- What Is Zenagamtide (Amycretin)?
- What Is Survodutide?
- What Is MariTide?
- What Is CagriSema?
- Tirzepatide vs semaglutide
Related research: What Is Retatrutide? GIP/GLP-1/Glucagon Triple Agonist — Research Overview; What Is Survodutide? Dual GLP-1/Glucagon Agonist — Research Overview; What Is VK2735? Viking Dual GIP/GLP-1 Agonist — Research Overview; What Is Zenagamtide (Amycretin)? Unimolecular GLP-1/Amylin Agonist — Research Overview.
CTA (SKU-gated / hard no): There is no orforglipron inventory inquiry path. Do not open a product draft. If a visitor asks to buy Foundayo, point them to licensed medical channels — not to SaiyanMed wholesale.
Research Use Only / not-a-product disclaimer
Educational content only. Summarizes public molecular, clinical-development, FDA, and company IR information for scientific literacy. It does not provide medical or veterinary advice, validated experimental protocols, dosing or reconstitution instructions, compounding recipes, or authorization for in-vivo work. Foundayo (orforglipron) is an FDA-approved prescription medicine for specific labeled uses — this article is not a substitute for the Prescribing Information or Medication Guide and is not a use guide for any research chemical. SaiyanMed does not sell orforglipron / Foundayo.
Sources & further reading
- FDA — Foundayo CNPV / NME approval press (2026-04-01) — fda.gov press
- FDA NDA 220934 approval package — accessdata.fda.gov PDF
- Lilly — FDA approves Foundayo (2026-04-01) — investor.lilly.com
- Lilly — ATTAIN-1 topline (2025-08-07) — investor.lilly.com
- Lilly Medical — ATTAIN-1 summary — medical.lilly.com
- Lilly — ACHIEVE-4 topline (2026-04-16) — investor.lilly.com
- ClinicalTrials.gov ATTAIN-1 — NCT05869903
- ClinicalTrials.gov ATTAIN-2 — NCT05872620
- ClinicalTrials.gov ACHIEVE-4 — NCT05803421
- NEJM ATTAIN-1 — DOI 10.1056/NEJMoa2511774
- PNAS LY3502970 structure — DOI 10.1073/pnas.2014879117